drugset / Trial / NCT02019329
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blinded, placebo-controlled study will investigate the safety, tolerability, and pharmacokinetics of multiple doses of RO5545965 administered orally to psychiatrically stable patients with schizophrenia receiving risperidone.
Timeline
- Start
- 2014-01
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO5545965 | Unknown | — | Oral |
| Background | Risperidone | Other / unclassified | 4 mg | Oral |